Ophthotech Corporation (NASDAQ:OPHT) SVP Barbara A. Wood sold 5,119 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $2.58, for a total transaction of $13,207.02. Following the completion of the sale, the senior vice president now owns 13,451 shares in the company, valued at $34,703.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Ophthotech Corporation (NASDAQ OPHT) opened at 2.65 on Tuesday. The company’s market cap is $95.01 million. Ophthotech Corporation has a one year low of $2.24 and a one year high of $65.96. The company’s 50 day moving average is $2.57 and its 200 day moving average is $3.63.
Ophthotech Corporation (NASDAQ:OPHT) last posted its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.31) by $0.11. The business had revenue of $1.66 million during the quarter, compared to the consensus estimate of $1.94 million. On average, equities analysts predict that Ophthotech Corporation will post ($3.88) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/18/barbara-a-wood-sells-5119-shares-of-ophthotech-corporation-opht-stock-updated.html.
Separately, Zacks Investment Research raised shares of Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Tuesday, May 2nd. Twelve research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $53.53.
Several hedge funds have recently modified their holdings of OPHT. Gabelli Funds LLC boosted its stake in shares of Ophthotech Corporation by 100.0% in the fourth quarter. Gabelli Funds LLC now owns 38,000 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 19,000 shares during the period. Creative Planning boosted its stake in shares of Ophthotech Corporation by 4,867.3% in the second quarter. Creative Planning now owns 46,941 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 45,996 shares during the period. SG Americas Securities LLC boosted its stake in shares of Ophthotech Corporation by 67.7% in the first quarter. SG Americas Securities LLC now owns 50,867 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 20,537 shares during the period. Teachers Advisors LLC boosted its stake in shares of Ophthotech Corporation by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 52,243 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 2,999 shares during the period. Finally, Tudor Investment Corp Et Al boosted its stake in shares of Ophthotech Corporation by 844.8% in the fourth quarter. Tudor Investment Corp Et Al now owns 67,023 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 59,929 shares during the period. 73.82% of the stock is currently owned by institutional investors and hedge funds.
Ophthotech Corporation Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.